
    
      In this study, patients with local recurrence of esophageal carcinoma without distant
      metastasis were randomly divided into experimental group and control group by Block
      randomization. In the experimental group, patients with local recurrence were treated with
      Camrelizumab combined with concurrent chemoradiotherapy. Followed up for 3 years to observe
      the objective remission rate and disease-free survival. In the control group, patients with
      local recurrence were treated with placebo combined with concurrent chemoradiotherapy.
      Followed up for 3 years to observe the objective remission rate and disease-free survival.
    
  